A Study Assessing Use of Regorafenib In The Real-Life Clinical Practice: Data From The Czech CORECT Registry.
Latest Information Update: 02 Jan 2019
Price :
$35 *
At a glance
- Drugs Regorafenib (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- 15 Oct 2016 New trial record
- 14 Sep 2016 Results published in the Targeted Oncology Journal.